SciBX
Science-Business eXchange

THE DISTILLERY

This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Overexpression of exportin 5 (XPO5) and eukaryotic translation initiation factor 2C 2 (EIF2C2; AGO2) to increase the efficacy and safety of small hairpin RNA therapeutics	Mouse studies suggest that increasing XPO5 and AGO2 expression could improve the safety and efficacy of shRNA therapeutics. In mice that overexpressed Xpo5 and Ago2, which are required for proper RNAi processing, shRNA function was prolonged and shRNA-associated hepatotoxicity was reduced compared with those in mice with normal Xpo5 and Ago2 expression. Next steps could include identifying therapeutic strategies to overexpress XPO5 and AGO2. *SciBX* **3**(33); doi:10.1038/scibx.2010.1027 **Published online Aug. 26, 2010**	Patent and licensing status unavailable	Grimm, D. *et al. J. Clin. Invest.*; published online Aug. 9, 2010; doi:10.1172/JCI43565 **Contact:** Mark A. Kay, Stanford University, Stanford, Calif. e-mail: markay@stanford.edu